· .		
For Internal Use Only	Submit 1 Original	OMB Approval No.:
Sec File No. 91 -	and 9 Copies	SECUTE Apires:
		Estimated average burden hotters per response: 2.00
91-1593	UNITED STATE SECURITIES AND EXCHANG Washington, D.C. 2 FORM 19b-4(e)	E COMMISSION 0549 APR I 8 2007
	equired of a Self-Regulatory Organ roduct Pursuant to Rule 19b-4(e) t ALL INSTRUCTIONS PRIOR TO	nization Wisting and Trading a New Under the Securities Exchange Act of 1934 O COMPLETING FORM
Part I	Initial Listin	
	ization Listing New Derivative Secu	
2. Type of Issuer of New Derivativ Open-end Management Invest		ouse, broker-dealer, corporation, etc.):
3. Class of New Derivative Securit Investment Company Units		
 Name of Underlying Instrument HealthSharesTM Respiratory/P 	: 'ulmonary Index	07052809
5. If Underlying Instrument is an In Narrow-Based	ndex, State Whether it is Broad-Base	ed or Narrow-Based:
6. Ticker Symbol(s) of New Derive HHR	ative Securities Product:	
New York Stock Exchange, Na 8. Settlement Methodology of New		
	r+3/Book entry only held in DTC. ve Securities Product (if applicable):	
Part II	Executi	
The undersigned represents that the or has duly delegated its approval to	governing body of the above-referen the undersigned for, the listing and televant trading rules, procedures, surv	ced Self-Regulatory Organization has duly approved, trading of the above-referenced new derivative reillance programs and listing standards.
Mary Yeager		
Title:		PROCESSED
Corporate Secretary Selephone Number:		
212) 656-2062		MAY 0 8 2007
Manual Signature of Official Respon	nsible for Form:	THOMISON FINANCIAL
Date: April 17, 2007	Act	Securities Exchange Act of 1934
SEC 2449 (1/99)	Section	19b-4
а	ENTO Rule	19b-4(e)
I	Public Availab	1 0